These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34478915)

  • 1. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples.
    Yamashita K; Watanabe S; Ishiki K; Miura M; Irino Y; Kubo T; Matsui J; Hagino K; Iwanaga S; Yoshida T
    Biochem Biophys Res Commun; 2021 Oct; 576():22-26. PubMed ID: 34478915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
    Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
    J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
    Janelidze S; Teunissen CE; Zetterberg H; Allué JA; Sarasa L; Eichenlaub U; Bittner T; Ovod V; Verberk IMW; Toba K; Nakamura A; Bateman RJ; Blennow K; Hansson O
    JAMA Neurol; 2021 Nov; 78(11):1375-1382. PubMed ID: 34542571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy.
    Yamashita K; Miura M; Watanabe S; Ishiki K; Arimatsu Y; Kawahira J; Kubo T; Sasaki K; Arai T; Hagino K; Irino Y; Nagai K; Verbel D; Koyama A; Dhadda S; Niiro H; Iwanaga S; Sato T; Yoshida T; Iwata A
    Alzheimers Res Ther; 2022 Jun; 14(1):86. PubMed ID: 35739591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay.
    Iino T; Watanabe S; Yamashita K; Tamada E; Hasegawa T; Irino Y; Iwanaga S; Harada A; Noda K; Suto K; Yoshida T
    J Appl Lab Med; 2021 Jul; 6(4):834-845. PubMed ID: 33462584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
    Rippon B; Palta P; Tahmi M; Sherwood G; Soto L; Cespedes S; Mesen Y; He H; Laing K; Moreno H; Teresi J; Razlighi Q; Brickman AM; Zetterberg H; Luchsinger JA
    J Alzheimers Dis; 2022; 87(3):1229-1238. PubMed ID: 35466933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
    Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
    Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.
    Mehta PD; Patrick BA; Miller DL; Coyle PK; Wisniewski T
    J Alzheimers Dis; 2020; 78(3):1237-1244. PubMed ID: 33252086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
    Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O
    J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The accuracy and robustness of plasma biomarker models for amyloid PET positivity.
    Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ
    Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer's Disease: a Meta-analysis.
    Zhang S; Huang SY; An XB; Zeng L; Ai J
    J Mol Neurosci; 2020 Jun; 70(6):861-870. PubMed ID: 32125624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.